课题基金 / 基金详情

IMPACT OF GENETICS ON METFORMIN PHARMACOKINETICS

IMPACT OF GENETICS ON METFORMIN PHARMACOKINETICS
遗传学对二甲双胍药代动力学的影响
批准号:
7202619
负责人:
KATHLEEN M GIACOMINI
金额:
$1.22万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-04-01 至 2006-03-31

项目摘要

项目成果

KATHLEEN M GIACOMINI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We have now completed three years of a four-year cycle. The primary aim of the new program direction team of the GCRC during this time was to address shortcomings identified in previous reviews and to continue to build our program for the future. We have completed the renovation of our inpatient unit and now have a state-of-the-art facility to conduct clinical research. We have relocated our Core Laboratory to new, updated and convenient space near the inpatient unit. We have improved our productivity in all spheres of activity, with steady growth in number of A days and visits, number of protocols, number and diversity of investigators, increased number of medical students and post-doctoral trainees on the unit and expansion of the scope of training activities. This has been accompanied by a substantial increase in publication productivity by GCRC investigators. Our new Research Subject Advocate (RSA) program has played an important role in assisting and educating GCRC investigators in the areas of research subject consent, safety monitoring and regualtory compliance. The Core Laboratory expanded its services in genomics and other DNA technologies, and our new Exercise Physiology and Body Composition Laboratory has been providing services to a growing number of investigators. The level of activiy and excitement on the GCRC has never been higher. In this competing renewal proposal, 66 different principal investigators will perform 89 protocols in several areas including genetic epidemiology of connective tissue diseases and other disorders, pharmacogenetics, dementia research, gene expression profiling in cancer, HIV natural history and pathogenesis, exercise physiology in chronic diseases, and metabolic research with an emphasis on pathogenesis and treatment obesity, hypertension, bone loss and diabetes mellitus. These complement several other already active programs including oncology and psychopharmacology of drug addiction. These areas cover many of the emerging critical health issues as the population ages. Our focus over the next 5 years will be to continue to expand training on the GCRC; continue to expand our protocol diversity; and invest in and expand new laboratory and informatics technologies to allow the GCRC investigators to meet the research challenges of the future. To this end, we are requesting new resources to expand our services in database design, genomics capabilities and exercise physiology. As we do so, we will continue to perform this research with the highest standards of patient care, ethics, safety and regulatory compliance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transporter Elucidation Center at the University of California, San Francisco
Characterizing the physiological and pharmacological roles of SLC22A24
Characterizing the physiological and pharmacological roles of SLC22A24
Characterizing the physiological and pharmacological roles of SLC22A24
海外基金